Novotech, a global full-service clinical research organisation (CRO), has agreed to acquire Agilex Biolabs. The deal will strengthen Novotech’s bioanalytical capabilities in Australia. Novotech announced the agreement with a wholly owned subsidiary of Healius Limited. Healius is a leading Australian healthcare company listed on the ASX as HLS. The transaction will bring Agilex Biolabs into Novotech’s growing global clinical development network.
Agilex Biolabs operates as a specialist bioanalytical laboratory business. The company is headquartered in Adelaide, Australia. Its addition will expand Novotech’s existing laboratory capabilities across Asia. The acquisition will also strengthen Novotech’s support for biotech and pharmaceutical sponsors. In addition, it will provide customers with greater access to specialist research services in Australia.
Australia remains an attractive destination for early-phase clinical research. Therefore, Novotech expects the expanded capabilities to support customers conducting clinical development programs.
“Agilex has an outstanding scientific reputation. This acquisition enhances Novotech’s offering in Australia, bringing together bioanalytical science and research capabilities to deliver innovative and ground-breaking research. We look forward to welcoming the Agilex team,” said Dr Anand Tharmaratnam, Chief Executive Officer of Novotech.
The statement highlights the scientific value of the transaction. It also reflects Novotech’s focus on strengthening its Australian research operations.
Expanding Bioanalytical Research Capabilities
The acquisition will add specialist bioanalytical expertise to Novotech’s existing services. As a result, the company can offer broader research and development support in Australia. Novotech already operates a global clinical development platform. Its existing laboratory network covers several markets across Asia. Agilex Biolabs will add further scientific and laboratory expertise to this network.
The combined capabilities will support biotech and pharmaceutical companies throughout their development programs. Moreover, customers can access clinical research and bioanalytical services through a broader platform. The deal also supports Novotech’s strategy of expanding its scientific capabilities. The company aims to provide responsive R&D support to sponsors worldwide.
Supporting Biotech and Pharmaceutical Sponsors
Agilex Biolabs brings specialist bioanalytical laboratory capabilities to Novotech. These capabilities can support research activities for biotech and pharmaceutical companies. Bioanalytical services play an important role in clinical development. They help research teams generate and evaluate data during drug development programs.
Therefore, the acquisition can broaden Novotech’s support for sponsors operating in Australia. It also adds scientific capabilities to the company’s existing clinical research infrastructure. Australia offers a strong environment for early-stage clinical research. Consequently, expanded local capabilities can help sponsors access relevant research services more efficiently.
The transaction also creates an opportunity for Agilex Biolabs’ employees. Its customers and team members can become part of a larger global clinical research organisation.
“The sale provides customers and team members of Agilex Biolabs with the opportunity to join an established and global business in Novotech, which has expertise in providing services to major biotechnology and pharmaceutical customers” said Paul Anderson, Managing Director & CEO of Healius Limited.
The acquisition therefore brings together two established organisations. It combines Agilex Biolabs’ specialist laboratory expertise with Novotech’s global clinical development capabilities.
Transaction Remains Subject to Conditions
Novotech and Healius have reached an agreement for the proposed acquisition. However, the transaction has not yet completed. Completion remains subject to customary conditions. These conditions include receiving the required regulatory clearances. Once completed, the acquisition will further develop Novotech’s presence in Australia. It will also add specialist bioanalytical capabilities to the company’s broader laboratory network.
For biotech and pharmaceutical sponsors, the expanded platform can provide additional research support. At the same time, Novotech can strengthen its position within Australia’s early-phase clinical research market. The transaction reflects continued activity within the clinical research and healthcare services sector. It also highlights the growing importance of integrated clinical development and bioanalytical capabilities.
Novotech expects the acquisition to enhance its offering for customers in Australia. Meanwhile, Agilex Biolabs will bring its specialist scientific expertise into Novotech’s global organisation. The transaction will move forward after the completion of the required conditions and regulatory clearances.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
